Upgrade to SI Premium - Free Trial

BTIG on Compass Pathways (CMPS): 'COMP360 is shaping up as clinically meaningful'

March 30, 2026 4:58 PM
BTIG analyst Thomas Shrader reiterated a Buy rating and $14.00 price target on Compass Pathways (NASDAQ: CMPS)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments